A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01430091
First received: September 6, 2011
Last updated: October 5, 2012
Last verified: October 2012

September 6, 2011
October 5, 2012
September 2011
October 2011   (final data collection date for primary outcome measure)
  • Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to the Last Measureable Concentration (AUC[0-tlast]) of Prasugrel's Active Metabolite (PRAS-AM) [ Time Frame: Pre-dose up to 8 hours post-dose after each treatment ] [ Designated as safety issue: No ]
  • Pharmacokinetics: Maximum Concentration (Cmax) of Prasugrel's Active Metabolite (PRAS-AM) [ Time Frame: Pre-dose up to 8 hours post-dose after each treatment ] [ Designated as safety issue: No ]
  • Pharmacokinetics: Time of Maximum Concentration (Tmax) of Prasugrel's Active Metabolite (PRAS-AM) [ Time Frame: Pre-dose up to 8 hours post-dose after each treatment ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01430091 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
Relative Bioavailability of a Prasugrel Paediatric Orally Disintegrating Tablet Formulation Compared to the Tablet in Healthy Adult Subjects

This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Sickle Cell Disease
  • Drug: Prasugrel (clinical formulation)
    Administered orally
    Other Names:
    • LY640315
    • Effient®
    • Efient®
  • Drug: Prasugrel (Orally Disintegrating Tablet [ODT])
    Administered orally
    Other Names:
    • LY640315
    • Effient®
    • Efient®
  • Active Comparator: Prasugrel clinical formulation
    A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
    Intervention: Drug: Prasugrel (clinical formulation)
  • Experimental: Prasugrel (ODT) - on tongue
    A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
    Intervention: Drug: Prasugrel (Orally Disintegrating Tablet [ODT])
  • Experimental: Prasugrel (ODT) - apple juice
    A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
    Intervention: Drug: Prasugrel (Orally Disintegrating Tablet [ODT])
  • Experimental: Prasugrel (ODT) - chewed
    A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
    Intervention: Drug: Prasugrel (Orally Disintegrating Tablet [ODT])
  • Experimental: Prasugrel (ODT) - under tongue
    A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
    Intervention: Drug: Prasugrel (Orally Disintegrating Tablet [ODT])
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Overtly healthy males or females, as determined by medical history and physical examination
  • Are either women who are of child-bearing potential, surgically sterilised or defined as post-menopausal. Female subjects of child-bearing potential (not surgically sterilised between menarche and menopause) must have a negative pregnancy test at the time of screening and must be using a reliable method of birth control. These include tubal ligation, an intrauterine device which has been in place for at least 3 months, the oral contraceptive pill which has been taken, without difficulty, for at least 3 months, or an approved hormonal implant. Barrier methods alone (condoms or diaphragm/cap) are not acceptable, but must be used in conjunction with a chemical method, that is, spermicidal gel. A woman is presumed to be post-menopausal if she has had amenorrhoea for greater than 12 months alone or amenorrheic for 6 to 12 months and has a serum oestradiol concentration <73 picomoles per liter (pmol/L) (20 picograms per milliliter [pg/mL]) (not applicable for women on hormone replacement therapy [HRT; oestrogen]) and a follicle stimulating hormone (FSH) concentration >40 international units per liter (IU/L).
  • Have clinical laboratory test results within normal reference range for the investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • Between the body mass index (BMI) of 18.5 and 32.0 kilograms per meter squared (kg/m^2), inclusive
  • Have acceptable blood pressure (BP) and heart rate (HR) (supine) as determined by the investigator
  • Have venous access sufficient to allow blood sampling
  • Are reliable and willing to make themselves available for the duration of the study, and will abide by the research unit policy and procedure and study restrictions
  • Have given written informed consent approved by Lilly and the Ethical Review Board (ERB) governing the site

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data, as determined by the investigator
  • Evidence of significant active neuropsychiatric disease
  • Have a history or presence of significant bleeding disorders, that is, haematemesis, melaena, severe or recurrent epistaxis, haemoptysis, haemorrhage, clinically overt haematuria, or intracranial haemorrhage
  • Have a history (within the last 5 years) or presence of gastric ulcers. Previous history of duodenal ulcer is acceptable but must have been successfully surgically or medically treated with no further evidence of disease in the past 6 months (from screening)
  • Have a personal or family history of coagulation or bleeding disorders or reasonable suspicion of vascular malformations, for example, cerebral haemorrhage, aneurysm, or premature stroke (cerebrovascular accident <65 years of age)
  • Have a self-reported history of significant bleeding from trauma (for example, prolonged bleeding after tooth extraction)
  • Are pre-menopausal females with a history or presence of menorrhagia within the last 5 years (from screening)
  • Have clinically significant out of range values for prothrombin time (PT), activated partial thromboplastin time (APTT), or platelet count at screening
  • Have repeatedly reported positive results (at least 2 separate samples) on the faecal occult blood examination
  • Have a history of major surgery within 3 months of screening
  • Have planned surgery within 14 days after the last study day
  • Have a clinically significant abnormality in fundoscopic examination or petechiae examination
  • Have any other clinically significant abnormality following the investigator's review of the prestudy physical examination, electrocardiogram (ECG) and clinical (safety) laboratory tests
  • Regularly use known drugs of abuse and/or show unacceptable positive findings on urinary drug screening
  • Have known allergies or significant hypersensitivity to prasugrel or related drugs, or a history of relevant allergic drug reactions of any origin
  • Have donated blood of more than 500 mL within the previous 1 month before prasugrel administration
  • Show evidence of positive human immunodeficiency virus (HIV) antibodies
  • Show evidence of positive hepatitis C antibody
  • Show evidence of positive hepatitis B surface antigen
  • Have a regular alcohol intake greater than 21 units/week for males or 14 units/week for females or are unwilling to comply with the alcohol consumption requirements from 48 hours prior to the first dose of prasugrel until discharge from the clinical research unit (CRU) after the final Pharmacokinetics (PK) sample of Period 5 has been taken. One unit of alcohol is equal to 8 g ethanol
  • Smoke 10 or more cigarettes per day
  • Use prescription, over the counter or herbal medications that cannot safely be discontinued within 14 days prior to prasugrel administration. Exceptions: subjects may continue thyroid replacement therapy, HRT (oestrogen), contraceptives and certain medications that are inhaled or applied to the skin, eyes, or nose. The influenza vaccine may also be administered; however this must be at least 72 hours before any prasugrel dose
  • Use proton pump inhibitors, antacids, or H2 antagonists, which may impact stomach pH
  • Have participated in a study involving administration of an investigational compound within the 30 days prior to prasugrel administration
  • Have any other condition that, in the opinion of the principal investigator increases the risk to the study subject or decreases the likelihood of obtaining reliable results from the study
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01430091
13040, H7T-EW-TADQ
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP